Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Current Leases (2022 - 2025)

Ovid Therapeutics' Current Leases history spans 4 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Current Leases rose 7.26% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $1.4 million, up 7.26%, while the annual FY2025 figure was $1.4 million, 7.26% up from the prior year.
  • Current Leases reached $1.4 million in Q4 2025 per OVID's latest filing, up from $1.4 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $1.4 million in Q4 2025 to a low of $533946.0 in Q4 2022.
  • Average Current Leases over 4 years is $1.2 million, with a median of $1.3 million recorded in 2024.
  • Peak YoY movement for Current Leases: surged 133.36% in 2023, then rose 7.2% in 2025.
  • A 4-year view of Current Leases shows it stood at $533946.0 in 2022, then soared by 133.36% to $1.2 million in 2023, then increased by 7.22% to $1.3 million in 2024, then grew by 7.26% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Current Leases are $1.4 million (Q4 2025), $1.4 million (Q3 2025), and $1.4 million (Q2 2025).